Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
The dataset provides insight to nearly 80% of the US healthcare system, with patient-level data from all provider types.
- The dataset provides insight to nearly 80% of the US healthcare system, with patient-level data from all provider types.
- Referring to the details of the publication below, these real-world data showed that healthcare resource utilization, such as CINV-related visits were significantly lower after AKYNZEO® compared to fosaprepitant/palonosetron (APPA).
- CINV-related healthcare costs were also statistically and/or numerically lower for patients receiving AKYZNEO® compared to APPA.
- There remains a gap between expected and actual patient outcomes as clinicians translate trial data and clinical guidelines into practice.